APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:APLI - CA03783R1073 - Common Stock
0.02 CAD
-0.01 (-20%)
We assign a fundamental rating of 0 out of 10 to APLI. APLI was compared to 32 industry peers in the Pharmaceuticals industry. APLI may be in some trouble as it scores bad on both profitability and health. APLI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year APLI has reported negative net income.
APLI had a negative operating cash flow in the past year.
APLI had negative earnings in each of the past 5 years.
APLI had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
APLI's Return On Assets of -347.87% is on the low side compared to the rest of the industry. APLI is outperformed by 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -347.87% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
APLI has about the same amout of shares outstanding than it did 1 year ago.
APLI has more shares outstanding than it did 5 years ago.
APLI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -197.73, we must say that APLI is in the distress zone and has some risk of bankruptcy.
APLI has a worse Altman-Z score (-197.73) than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -197.73 |
ROIC/WACCN/A
WACC3.2%
2.3 Liquidity
A Current Ratio of 0.05 indicates that APLI may have some problems paying its short term obligations.
The Current ratio of APLI (0.05) is worse than 93.75% of its industry peers.
APLI has a Quick Ratio of 0.05. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
APLI has a worse Quick ratio (0.05) than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.77% over the past year.
Looking at the last year, APLI shows a very negative growth in Revenue. The Revenue has decreased by -87.87% in the last year.
APLI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.88% yearly.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.43%
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%2289.11%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APLI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for APLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:APLI (1/6/2026, 7:00:00 PM)
0.02
-0.01 (-20%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.84%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap2.43M
Revenue(TTM)100.40K
Net Income(TTM)-2.62M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 24.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -347.87% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-211.81%
ROA(5y)-203.41%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.93% | ||
| Cap/Sales | 0.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.05 | ||
| Quick Ratio | 0.05 | ||
| Altman-Z | -197.73 |
F-Score1
WACC3.2%
ROIC/WACCN/A
Cap/Depr(3y)78.19%
Cap/Depr(5y)66.91%
Cap/Sales(3y)1.99%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.43%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.87%
Revenue growth 3Y-58.35%
Revenue growth 5Y-12.88%
Sales Q2Q%2289.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y95.99%
OCF growth 3YN/A
OCF growth 5YN/A
APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ
What is the ChartMill fundamental rating of APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
ChartMill assigns a fundamental rating of 0 / 10 to APLI.CA.
What is the valuation status of APPILI THERAPEUTICS INC-CL A (APLI.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to APPILI THERAPEUTICS INC-CL A (APLI.CA). This can be considered as Overvalued.
What is the profitability of APLI stock?
APPILI THERAPEUTICS INC-CL A (APLI.CA) has a profitability rating of 0 / 10.